• Publications
  • Influence
MEK and the inhibitors: from bench to bedside
This review summarized new MEK inhibitors in clinical development, including pimasertib, refametinib, PD-0325901, TAK733, MEK162, RO5126766, WX-554, RO4987655, GDC-0973 (XL518), and AZD8330, and summarized new MAP kinase signaling pathways involving 7 MEK enzymes. Expand
Ibrutinib for B cell malignancies
The role of BTK in B-cell signaling, molecular interactions between B cell lymphoma/leukemia cells and their microenvironment, and clinical trials of the novel BTK inhibitor, ibrutinib (PCI-32765), in B cell malignancies were summarized. Expand
An unusual pancreatic mass: a case report and literature review
A case of obstructive jaundice due to pancreatic plasmacytoma as the initial presentation of multiple myeloma is presented. Expand
A case of phosphaturic mesenchymal tumor.
An unusual case of PMTMCT with widespread osseous metastases and without evidence of tumor-induced osteomalacia or phosphaturia is described. Expand
Recent Advances in the Management of Smoldering Multiple Myeloma
This review discusses identifying SMM patients who are at high risk of progression to sy-MM and recent development of new and early treatment strategies and ongoing clinical trials for these high-riskSMM patients. Expand